Developer docs
API playgroundTry for free, no card

Search company profiles

Accellix

Full company profile

uuid0000g3e

Namestring
Accellix
Legal namestring
Accellix, Inc.
Websiteurl
accellix.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Accellix, founded in 2017 (originally as LeukoDx, rebranded in July 2019) and headquartered in San Jose, California with R&D operations in Jerusalem, Israel, developed an automated benchtop flow cytometry platform purpose-built for quality control workflows inside cell and gene therapy GMP manufacturing suites. The core product integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based system that delivers cell phenotyping results in approximately 30 minutes, eliminating the need for centralized laboratory infrastructure, skilled flow cytometry technicians, and cold-chain reagent logistics. The platform combines a small-footprint fan-less instrument, single-use cartridges containing unitized dried reagents with 12-month room-temperature stability, a 6-color multiparametric assay architecture, and proprietary auto-classification software that dynamically defines cell subset boundaries without hard thresholds. Accellix's go-to-market centered on direct enterprise field sales targeting cell therapy manufacturers (CAR-T, TCR, NK, stem cell, iPSC applications) and blood bank and collection center customers such as the American Red Cross Cell and Gene Therapy Solutions, complemented by an exclusive bioMérieux distribution partnership across China, Japan, Australia, and South Korea. The business model follows a razor-and-blade structure with hardware instrument sales, recurring consumable cartridge revenue, maintenance and service contracts, and custom assay development services, generating revenue from over 20 enterprise biopharmaceutical customers by 2021. In January 2026, bioMérieux acquired 100% of Accellix for approximately €35 million in cash, integrating the platform into its Pharmaceutical Quality Control franchise alongside sterility, mycoplasma, and endotoxin testing offerings for the advanced therapy market.

Short descriptiontext

Accellix develops an automated benchtop flow cytometry platform with single-use microfluidic cartridges for rapid cell phenotyping quality control inside cell and gene therapy GMP manufacturing suites, serving biopharmaceutical manufacturers and blood banks. Acquired by bioMérieux in January 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Jose, United States
HQ citystring
San Jose
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
flow cytometry platforms, cell therapy QC, microfluidic assay cartridges, GMP manufacturing automation, cell phenotyping instruments
Industry2 codes
PRIMARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAJAK
Quality Control (QC) Testing Technologies for Biomanufacturing (release/stability assays, rapid microbiology)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Flow Cytometry Instrumentation
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument Sales
TypeHardware Sales
Description

Sale of the Accellix Instrument - a benchtop flow cytometer platform. Instrument includes 12-month warranty from date of installation.

accellix.com
2Assay/Cartridge Consumables
TypeHardware Sales
Description

Single-use microfluidic cartridges and assay kits with dried reagents. Each kit provides automated sample preparation, data acquisition and analysis for one cell sample. Assays have 12 months stability at room temperature.

accellix.com
3Maintenance and Service Contracts
TypeManaged Services
Description

Preventive maintenance per year per instrument, onsite service, and technical support. First year included with instrument purchase, subsequent years purchasable at reduced cost.

accellix.com
4Professional Services
TypeProfessional Services
Description

Training, maintenance, repairs, and other services as mutually agreed upon per purchase order or quote.

accellix.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Pricing details1 tier
1Quote-based instrument and consumable pricing
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available; quotes provided upon request. Enterprise sales motion with demo and quote request process.

accellix.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Accellix sells an automated benchtop flow cytometry platform that integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based system for GMP manufacturing quality control. The platform comprises the Accellix Instrument (hardware), Accellix Software, single-use microfluidic cartridges with dried reagents, and standard/custom assay kits that deliver cell phenotyping results in approximately 30 minutes for cell and gene therapy manufacturers and blood banks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 4-5x improvement in reproducibility when implementing Accellix and automating QC workflow
+4 more records
Product overview1 text field

Accellix offers a unified automated cell phenotyping platform consisting of the Accellix Instrument (benchtop flow cytometer hardware), Accellix Software, and Microfluidic Cartridges with integrated dried reagents. The platform automates the complete workflow from sample preparation through flow cytometry acquisition to data analysis, delivering results in under 30 minutes. The product portfolio includes Standard Assay Kits for common markers (T-Cell, Lymphocyte Subset panels) and Custom Assay Kits that can accommodate panels with up to 6 fluorophores. Algorithm-Based Autoanalysis provides automated data classification using proprietary algorithms. All components are designed for GMP manufacturing environments and point-of-need testing.

Product and service7 records
1Accellix Automated Cell Phenotyping Platform
CategoryFlow cytometry platform
Description

Unified automated benchtop flow cytometry platform that integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based workflow, delivering GMP-compliant QC results in under 30 minutes for cell and gene therapy manufacturers and blood banks.

2Accellix Instrument
CategoryHardware instrument
Description

Small-footprint benchtop flow cytometer platform with touchscreen interface, fan-less operation, 24/7 availability, and ethernet/wifi connectivity, designed for deployment inside GMP manufacturing suites with no calibration or user maintenance required.

3Accellix Software
CategorySoftware
Description

Configurable touchscreen software for QC workflows, including QR-coded cartridge protocol execution, 21 CFR Part 11 compliance, LIMS connectivity, and export of FCS, CSV, and PDF reports.

4Microfluidic Cartridge
CategoryConsumable
Description

Single-use microfluidic cartridge with unitized dried-down reagents and integrated fluorescent control beads that perform automated sample preparation, in-run instrument performance checks, and ratio-metric cell counting within a controlled microfluidic flow cell.

5Standard Assay Kits
CategoryConsumable assay
Description

Off-the-shelf fixed-panel assay kits (e.g., T-Cell and Lymphocyte Subset Assays) shipped as single-use microfluidic cartridges with dried reagent tubes and 12-month room-temperature stability for immediate use on the Accellix instrument.

6Custom Assay Kits
CategoryCustom consumable assay
Description

Bespoke assay development service that migrates customer flow cytometry panels (up to 6 fluorophores) onto the Accellix cartridge format, including n-1 and n-2 proof-of-concept kits, for proprietary cell therapy QC markers.

7Algorithm-Based Autoanalysis
CategorySoftware service
Description

Automated data analysis and auto-classification service that uses proprietary algorithms with dynamic boundary definition (no hard thresholds) to identify cell subsets, configured per customer assay requirements.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

bioMérieux acquired 100% of Accellix for approximately €35 million in cash in January 2026, increasing from its prior ~10% stake. The acquisition strengthens bioMérieux's Pharmaceutical Quality Control activity and adds cell purity and viability testing to its existing sterility, mycoplasma, and endotoxin testing portfolio for the advanced therapy market.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-09-24
Description

Strategic collaboration adding the Accellix Automated Cell Phenotyping Platform to Streck's CD-Chex Plus® (RUO) control. The integration allows users to assess Accellix platform performance and ensure reliable operation, supporting routine monitoring in fast-paced manufacturing environments without requiring separate or centralized lab infrastructure.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-03
Description

American Red Cross selected Accellix to provide instruments and assays at its CGTS collection sites to improve characterization of source materials used for cell therapy development. The Accellix Platform enables high-quality cell therapy source material characterization within 30 minutes at the point of collection, supporting timely shipment of leukopak products with Certificate of Analysis.

4bioMérieux (Asia Pacific)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-02-18
Description

bioMérieux designated as exclusive distributor of Accellix products in China, Japan, Australia, and South Korea. bioMérieux performs full range of sales, supply, and service activities in the Asia Pacific region. The partnership builds on bioMérieux's portfolio of ATMP quality control solutions.

accellix.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Major flow cytometry provider owned by Danaher, offering benchtop and high-end flow cytometers and cell sorting systems. Directly competes with Accellix in flow cytometry instrumentation with established presence in cell therapy and bioprocess QC markets.

TypeDirect peer
Description

Becton Dickinson's life sciences arm offers flow cytometry instruments (BD FACSCelesta, BD FACSDiscover) and a broad reagent portfolio for cell analysis. Competes with Accellix in providing flow cytometry solutions to cell therapy manufacturers and research laboratories.

TypeDirect peer
Description

Specializes in spectral flow cytometry platforms (Aurora, Northern Lights) with full-spectrum capabilities for high-parameter cell analysis. Competes with Accellix in the flow cytometry instrumentation market serving immunology and cell therapy research.

TypeDirect peer
Description

Provides cell therapy manufacturing tools including the MACSQuant flow cytometer and integrated cell processing platforms. Directly competes with Accellix by offering flow cytometry and cell analysis solutions tailored to cell and gene therapy manufacturing workflows.

5Sony Biotechnology
TypeDirect peer
Description

Offers cell sorters and flow cytometers (SH800, MA900) used in cell therapy manufacturing and research. Competes with Accellix in providing flow cytometry solutions with GMP-friendly features for cell therapy applications.

TypeBroad incumbent
Description

Major life sciences tools provider offering flow cytometry instruments (Attune, Bigfoot) alongside extensive reagent and cell therapy manufacturing portfolios. Provides overlapping capabilities to Accellix but as part of a much broader life sciences business.

TypeEmerging player
Description

Developer of microfluidic cell sorting and analysis platforms for cell therapy and biomedical research. Competes with Accellix in providing microfluidic-based flow cytometry tools targeting cell therapy manufacturing QC.

TypeEmerging player
Description

Specializes in flow cytometry data analysis software (FCS Express) used by cell therapy and immunology researchers. Adjacent to Accellix as a software-focused competitor offering automated cell analysis capabilities.

TypeOthers
Description

Provider of quality control materials and hematology controls for clinical and research labs. Strategic collaboration partner with Accellix integrating CD-Chex Plus control with the Accellix platform; serves an enabling role rather than direct competitor.

TypeEmerging player
Description

Offers automated, microfluidic-based cell analysis platforms (DropArray, Laminar Wash) for immunology and cell therapy research. Competes with Accellix by providing miniaturized, automated cell phenotyping solutions with reduced manual handling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accellix

Flow Cytometry Instrumentationaccellix.com

Accellix develops an automated benchtop flow cytometry platform with single-use microfluidic cartridges for rapid cell phenotyping quality control inside cell and gene therapy GMP manufacturing suites, serving biopharmaceutical manufacturers and blood banks. Acquired by bioMérieux in January 2026.

What Accellix does

Accellix, founded in 2017 (originally as LeukoDx, rebranded in July 2019) and headquartered in San Jose, California with R&D operations in Jerusalem, Israel, developed an automated benchtop flow cytometry platform purpose-built for quality control workflows inside cell and gene therapy GMP manufacturing suites. The core product integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based system that delivers cell phenotyping results in approximately 30 minutes, eliminating the need for centralized laboratory infrastructure, skilled flow cytometry technicians, and cold-chain reagent logistics. The platform combines a small-footprint fan-less instrument, single-use cartridges containing unitized dried reagents with 12-month room-temperature stability, a 6-color multiparametric assay architecture, and proprietary auto-classification software that dynamically defines cell subset boundaries without hard thresholds. Accellix's go-to-market centered on direct enterprise field sales targeting cell therapy manufacturers (CAR-T, TCR, NK, stem cell, iPSC applications) and blood bank and collection center customers such as the American Red Cross Cell and Gene Therapy Solutions, complemented by an exclusive bioMérieux distribution partnership across China, Japan, Australia, and South Korea. The business model follows a razor-and-blade structure with hardware instrument sales, recurring consumable cartridge revenue, maintenance and service contracts, and custom assay development services, generating revenue from over 20 enterprise biopharmaceutical customers by 2021. In January 2026, bioMérieux acquired 100% of Accellix for approximately €35 million in cash, integrating the platform into its Pharmaceutical Quality Control franchise alongside sterility, mycoplasma, and endotoxin testing offerings for the advanced therapy market.

Accellix firmographics

Firmographics
Name
Accellix
Legal name
Accellix, Inc.
Website
https://accellix.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
51–100 employees
Short description
Accellix develops an automated benchtop flow cytometry platform with single-use microfluidic cartridges for rapid cell phenotyping quality control inside cell and gene therapy GMP manufacturing suites, serving biopharmaceutical manufacturers and blood banks. Acquired by bioMérieux in January 2026.
Ownership category
akta.pro rank

Accellix industry classification

Industry
Product category
Flow Cytometry Instrumentation
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAJAK
Quality Control (QC) Testing Technologies for Biomanufacturing (release/stability assays, rapid microbiology)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Flow cytometry platforms
  • Cell therapy QC
  • Microfluidic assay cartridges
  • GMP manufacturing automation
  • Cell phenotyping instruments

Where Accellix is headquartered

Location

Headquarters

HQ city
San Jose
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Accellix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Instrument Sales: Sale of the Accellix Instrument - a benchtop flow cytometer platform. Instrument includes 12-month warranty from date of installation.
  2. Assay/Cartridge Consumables: Single-use microfluidic cartridges and assay kits with dried reagents. Each kit provides automated sample preparation, data acquisition and analysis for one cell sample. Assays have 12 months stability at room temperature.
  3. Maintenance and Service Contracts: Preventive maintenance per year per instrument, onsite service, and technical support. First year included with instrument purchase, subsequent years purchasable at reduced cost.
  4. Professional Services: Training, maintenance, repairs, and other services as mutually agreed upon per purchase order or quote.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based instrument and consumable pricing

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Accellix product offering

Product offering

Core offering

Accellix sells an automated benchtop flow cytometry platform that integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based system for GMP manufacturing quality control. The platform comprises the Accellix Instrument (hardware), Accellix Software, single-use microfluidic cartridges with dried reagents, and standard/custom assay kits that deliver cell phenotyping results in approximately 30 minutes for cell and gene therapy manufacturers and blood banks.

Product overview

Accellix offers a unified automated cell phenotyping platform consisting of the Accellix Instrument (benchtop flow cytometer hardware), Accellix Software, and Microfluidic Cartridges with integrated dried reagents. The platform automates the complete workflow from sample preparation through flow cytometry acquisition to data analysis, delivering results in under 30 minutes. The product portfolio includes Standard Assay Kits for common markers (T-Cell, Lymphocyte Subset panels) and Custom Assay Kits that can accommodate panels with up to 6 fluorophores. Algorithm-Based Autoanalysis provides automated data classification using proprietary algorithms. All components are designed for GMP manufacturing environments and point-of-need testing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Accellix Automated Cell Phenotyping Platform Unified automated benchtop flow cytometry platform that integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based workflow, delivering GMP-compliant QC results in under 30 minutes for cell and gene therapy manufacturers and blood banks.
  • Accellix Instrument Small-footprint benchtop flow cytometer platform with touchscreen interface, fan-less operation, 24/7 availability, and ethernet/wifi connectivity, designed for deployment inside GMP manufacturing suites with no calibration or user maintenance required.
  • Accellix Software Configurable touchscreen software for QC workflows, including QR-coded cartridge protocol execution, 21 CFR Part 11 compliance, LIMS connectivity, and export of FCS, CSV, and PDF reports.
  • Microfluidic Cartridge Single-use microfluidic cartridge with unitized dried-down reagents and integrated fluorescent control beads that perform automated sample preparation, in-run instrument performance checks, and ratio-metric cell counting within a controlled microfluidic flow cell.
  • Standard Assay Kits Off-the-shelf fixed-panel assay kits (e.g., T-Cell and Lymphocyte Subset Assays) shipped as single-use microfluidic cartridges with dried reagent tubes and 12-month room-temperature stability for immediate use on the Accellix instrument.
  • Custom Assay Kits Bespoke assay development service that migrates customer flow cytometry panels (up to 6 fluorophores) onto the Accellix cartridge format, including n-1 and n-2 proof-of-concept kits, for proprietary cell therapy QC markers.
  • Algorithm-Based Autoanalysis Automated data analysis and auto-classification service that uses proprietary algorithms with dynamic boundary definition (no hard thresholds) to identify cell subsets, configured per customer assay requirements.

Quantifiable outcome

  • 4-5x improvement in reproducibility when implementing Accellix and automating QC workflow
  • +4 more outcomes

Companies that use Accellix

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Accellix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature6 records

Accellix partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, strategic and core.

  • bioMérieuxflagshipStrategic or Co-development Partner · 22 January 2026bioMérieux acquired 100% of Accellix for approximately €35 million in cash in January 2026, increasing from its prior ~10% stake. The acquisition strengthens bioMérieux's Pharmaceutical Quality Control activity and adds cell purity and viability testing to its existing sterility, mycoplasma, and endotoxin testing portfolio for the advanced therapy market.
  • StreckstrategicStrategic or Co-development Partner · 24 September 2025Strategic collaboration adding the Accellix Automated Cell Phenotyping Platform to Streck's CD-Chex Plus® (RUO) control. The integration allows users to assess Accellix platform performance and ensure reliable operation, supporting routine monitoring in fast-paced manufacturing environments without requiring separate or centralized lab infrastructure.
  • American Red Cross Cell and Gene Therapy SolutionscoreStrategic or Co-development Partner · 3 December 2024American Red Cross selected Accellix to provide instruments and assays at its CGTS collection sites to improve characterization of source materials used for cell therapy development. The Accellix Platform enables high-quality cell therapy source material characterization within 30 minutes at the point of collection, supporting timely shipment of leukopak products with Certificate of Analysis.
  • bioMérieux (Asia Pacific)coreChannel Partner/ Reseller/ Distributor · 18 February 2021bioMérieux designated as exclusive distributor of Accellix products in China, Japan, Australia, and South Korea. bioMérieux performs full range of sales, supply, and service activities in the Asia Pacific region. The partnership builds on bioMérieux's portfolio of ATMP quality control solutions.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Accellix competitors and assessment

Company assessment

Direct peers

  • Beckman Coulter Life Sciences: Major flow cytometry provider owned by Danaher, offering benchtop and high-end flow cytometers and cell sorting systems. Directly competes with Accellix in flow cytometry instrumentation with established presence in cell therapy and bioprocess QC markets.
  • BD Biosciences: Becton Dickinson's life sciences arm offers flow cytometry instruments (BD FACSCelesta, BD FACSDiscover) and a broad reagent portfolio for cell analysis. Competes with Accellix in providing flow cytometry solutions to cell therapy manufacturers and research laboratories.
  • Cytek Biosciences: Specializes in spectral flow cytometry platforms (Aurora, Northern Lights) with full-spectrum capabilities for high-parameter cell analysis. Competes with Accellix in the flow cytometry instrumentation market serving immunology and cell therapy research.
  • Miltenyi Biotec: Provides cell therapy manufacturing tools including the MACSQuant flow cytometer and integrated cell processing platforms. Directly competes with Accellix by offering flow cytometry and cell analysis solutions tailored to cell and gene therapy manufacturing workflows.
  • Sony Biotechnology: Offers cell sorters and flow cytometers (SH800, MA900) used in cell therapy manufacturing and research. Competes with Accellix in providing flow cytometry solutions with GMP-friendly features for cell therapy applications.

Broad incumbents

  • Thermo Fisher Scientific: Major life sciences tools provider offering flow cytometry instruments (Attune, Bigfoot) alongside extensive reagent and cell therapy manufacturing portfolios. Provides overlapping capabilities to Accellix but as part of a much broader life sciences business.

Emerging players

  • NanoCellect Biomedical: Developer of microfluidic cell sorting and analysis platforms for cell therapy and biomedical research. Competes with Accellix in providing microfluidic-based flow cytometry tools targeting cell therapy manufacturing QC.
  • De Novo Software: Specializes in flow cytometry data analysis software (FCS Express) used by cell therapy and immunology researchers. Adjacent to Accellix as a software-focused competitor offering automated cell analysis capabilities.
  • Curiox Biosystems: Offers automated, microfluidic-based cell analysis platforms (DropArray, Laminar Wash) for immunology and cell therapy research. Competes with Accellix by providing miniaturized, automated cell phenotyping solutions with reduced manual handling.

Others

  • Streck: Provider of quality control materials and hematology controls for clinical and research labs. Strategic collaboration partner with Accellix integrating CD-Chex Plus control with the Accellix platform; serves an enabling role rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Accellix social profiles

Digital presence

Accellix compliance and trust

Trust signal

Compliance2 records

Accellix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accellix leadership team

Management profile

Number of profiles

Profiles9 records

Accellix funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accellix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accellix

What does Accellix do?

Accellix sells an automated benchtop flow cytometry platform that integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based system for GMP manufacturing quality control. The platform comprises the Accellix Instrument (hardware), Accellix Software, single-use microfluidic cartridges with dried reagents, and standard/custom assay kits that deliver cell phenotyping results in approximately 30 minutes for cell and gene therapy manufacturers and blood banks.

Is Accellix a public or private company?

Accellix is a private company. It is classified as corporate owned and is currently acquired.

When was Accellix founded?

Accellix was founded in 2017. It employs 51 to 100 people.

Where is Accellix based?

Accellix is headquartered in San Jose, United States, in the North America region.

How does Accellix make money?

Four revenue lines are on record. Instrument Sales are the primary driver. The others are assay/Cartridge Consumables, maintenance and Service Contracts and professional Services.

Who are Accellix's main competitors?

Direct peers on record are Beckman Coulter Life Sciences, BD Biosciences, Cytek Biosciences, Miltenyi Biotec and Sony Biotechnology. Thermo Fisher Scientific is listed as a broad incumbent. Emerging players are NanoCellect Biomedical, De Novo Software and Curiox Biosystems. Streck is listed as an others.

Does Accellix have an API?

No public API is recorded for Accellix.

What industry is Accellix in?

Accellix's product category is Flow Cytometry Instrumentation. Its primary akta.pro industry code is HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics, with a secondary code of HLAAAJAK, Quality Control (QC) Testing Technologies for Biomanufacturing (release/stability assays, rapid microbiology). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialGlobal Release Testing For Gene Therapy Market Report 2026 Capitalize On 16.5% CAGR Through 2030 As Thermo Fisher, Lonza, Eurofins And Wuxi Apptec Accelerate Automated QCThe global release testing for gene therapy market is projected to grow from $1.43 billion in 2025 to $1.67 billion in 2026, a 16.3% CAGR, and reach $3.08 billion by 2030 at 16.5% CAGR. Growth is driven by commercialization, regulatory scrutiny, and adoption of automated QC platforms, with bioMerieux acquiring Accellix for $41 million.EIN PresswireWith 10.1% CAGR, Rapid Microbiology Testing Market to reach USD 16.91 Billion by 2035The global rapid microbiology testing market is projected to grow from USD 7.11 billion in 2026 to USD 16.91 billion by 2035, a 10.1% CAGR. Growth is driven by FDA reclassification of mass-spectrometry systems, pharmaceutical automation investment exceeding USD 3.2 billion, and regulatory mandates for faster testing.Technology NetworksTransforming Cell Therapy Manufacturing With Cellular Starting Material Immunophenotyping at the Point of CollectionTechnology Networks interviewed Dr. Félix Alejandro Montero Julian, vice president of scientific affairs at Accellix, to discuss how variability in cellular starting materials from leukapheresis products is a leading cause of manufacturing failures and inconsistent clinical outcomes in CAR T-cell therapy. The article explores how traditional flow cytometry creates bottlenecks due to manual workflows and centralized lab requirements, while FDA guidance and industry organizations are calling for standardized immunophenotyping at the point of collection to ensure product quality. Accellix's benchtop platform automates the immunophenotyping workflow using single-use microfluidic cartridges, delivering results in approximately 30 minutes to enable near real-time decisions on leukopak acceptance and in-process monitoring.EIN PresswirePharmaceutical Microbiology QC Testing Market Growth Projections US$10.84 billion by 2033, Growth in Quality AssuranceAccording to market research from DataM Intelligence, the global pharmaceutical microbiology QC testing market was valued at US$3.52 billion in 2024 and is projected to reach US$10.84 billion by 2033, growing at a CAGR of 13.1%. North America held the dominant regional market share of 38.42% in 2025, driven by a strong pharmaceutical manufacturing base and high regulatory standards. Key company developments include BIOMÉRIEUX's acquisition of Accellix Inc. in January 2026, alongside product launches from Thermo Fisher Scientific, Biotactical B.V., and service expansions from Charles River Laboratories and FUJIFILM Wako.The Mass Spectrometry Web PortalbioMérieux S.A.. (1/22/26). "Press Release: bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies". Marcy l’Étoile.bioMérieux S.A. has completed the acquisition of Accellix, a US-based company specializing in rapid automated flow cytometry solutions for cell and gene therapy quality control, increasing its stake from approximately 10% to 100%. The transaction, valued at around €35 million in cash, gives bioMérieux access to Accellix's compact platform that delivers quality control results in under 30 minutes, enabling real-time monitoring during cell therapy manufacturing. The acquired company employs approximately 70 people across two locations in San José, California (United States) and Jerusalem, Israel.InvestorsinhealthcareFrance: bioMérieux completes its offering for cell and gene therapies with acquisition of AccellixFrance-based bioMérieux has completed its acquisition of Accellix, buying the remaining share capital to take its stake from approximately 10% to 100% for around €35 million in cash. Accellix is a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control, employing roughly 70 people across locations in the US and Israel. The acquisition completes bioMérieux's cell and gene therapy offering by adding cell purity and viability testing to its existing sterility, mycoplasma, and endotoxin testing capabilities.BiomerieuxbioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced TherapiesbioMérieux has acquired Accellix to enhance pharmaceutical quality control and accelerate advanced therapies. This acquisition aims to strengthen bioMérieux's capabilities in innovative diagnostics and therapy development.AccellixbioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies - AccellixbioMérieux, a French in vitro diagnostics company, has completed the acquisition of Accellix, a US-based company specializing in rapid automated flow cytometry solutions for cell and gene therapy quality control. The transaction, valued at approximately €35 million in cash, increased bioMérieux's stake from roughly 10% to 100% ownership of Accellix. The acquisition strengthens bioMérieux's Pharmaceutical Quality Control activity and positions the company to offer expanded quality control solutions for the advanced therapy market, adding cell purity and viability testing to its existing sterility, mycoplasma, and endotoxin testing portfolio.FinSMEsAccellix Raises $9.5M in Series D FundingAccellix raised $9.5M in Series D funding led by bioMérieux, with existing investors converting $8.5M in convertible notes, totaling $18M. The funds will expand market reach for its cell therapy QC system. Michael Reynier will join the board.Business Wire BlogAccellix, the Cell Therapy QC Company Raises $9.5 Million Series D RoundAccellix raised $9.5 million in a Series D round led by bioMérieux, with existing investors converting $8.5 million in convertible notes for a total of $18 million. The funds will expand market reach for its cell therapy QC platform. bioMérieux's VP will join Accellix's board.